Microbicide safety and effectiveness: an overview of recent clinical trials.

PURPOSE OF REVIEW

This review summarizes findings from recent vaginal microbicide safety and effectiveness trials and discusses the challenges associated with undertaking these trials.

RECENT FINDINGS

In safety trials, there has been a focus on the development of biomarkers of genital irritation. Recent safety studies have expanded the range of genital toxicity measures to include biomarkers of mucosal immunity, detection of haemoglobin in cervicovaginal lavage specimens and microbicide-induced vaginal flora changes. Four effectiveness trials have been stopped prematurely, two due to a lower than estimated HIV incidence rate, one as a result of an interim analysis suggesting increased risk of HIV acquisition among participants receiving active product, and one as a safety precaution. One effectiveness trial was completed and showed no reduction in HIV acquisition among participants receiving active product, and one ongoing effectiveness trial was modified by discontinuing a trial arm. Methodological challenges faced by these trials have included accurately estimating HIV incidence and pregnancy rates in trial populations, and improving adherence to and measurement of study product use.

SUMMARY

Validated safety and surrogate efficacy endpoints and standard ways of reporting them are being pursued. Focus has shifted to antiretrovirals containing microbicides, some of which may be used independent of coitus. Research on how to improve and measure adherence should continue.